Lantheus Holdings, Inc. $LNTH Stock Sold by Reinhart Partners LLC.

Reinhart Partners LLC. trimmed its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 24.5% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,207,900 shares of the medical equipment provider’s stock after selling 391,479 shares during the period. Lantheus accounts for 2.9% of Reinhart Partners LLC.’s portfolio, making the stock its 11th largest holding. Reinhart Partners LLC.’s holdings in Lantheus were worth $120,222,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of LNTH. Legal & General Group Plc bought a new stake in Lantheus during the 2nd quarter valued at approximately $9,786,000. Carmignac Gestion increased its holdings in shares of Lantheus by 0.9% in the second quarter. Carmignac Gestion now owns 1,340,100 shares of the medical equipment provider’s stock worth $148,671,000 after purchasing an additional 12,100 shares during the last quarter. Epoch Investment Partners Inc. lifted its position in shares of Lantheus by 59.4% in the first quarter. Epoch Investment Partners Inc. now owns 649,751 shares of the medical equipment provider’s stock worth $49,284,000 after buying an additional 242,222 shares in the last quarter. Assenagon Asset Management S.A. lifted its position in shares of Lantheus by 440.3% in the second quarter. Assenagon Asset Management S.A. now owns 714,980 shares of the medical equipment provider’s stock worth $79,320,000 after buying an additional 582,661 shares in the last quarter. Finally, Hsbc Holdings PLC bought a new position in Lantheus during the second quarter valued at approximately $2,273,000. 99.06% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

LNTH has been the subject of several research analyst reports. B. Riley Financial cut Lantheus from a “buy” rating to a “hold” rating in a report on Monday, August 17th. William Blair set a $102.50 target price on Lantheus in a research report on Monday, August 3rd. Mizuho lowered their target price on Lantheus from $120.00 to $115.00 and set an “outperform” rating for the company in a research report on Wednesday, July 29th. TD Cowen lowered shares of Lantheus from a “buy” rating to a “hold” rating and cut their target price for the company from $110.00 to $102.50 in a report on Monday, August 3rd. Finally, CJS Securities cut shares of Lantheus from a “market outperform” rating to a “market perform” rating in a research report on Tuesday, August 4th. Four research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Lantheus currently has an average rating of “Hold” and an average target price of $108.11.

Lantheus Stock Performance

LNTH stock opened at $100.15 on Friday. Lantheus Holdings, Inc. has a twelve month low of $50.15 and a twelve month high of $111.86. The firm has a market cap of $6.54 billion, a price-to-earnings ratio of 24.19 and a beta of -0.06. The business’s fifty day simple moving average is $100.49 and its two-hundred day simple moving average is $96.87. The company has a quick ratio of 2.89, a current ratio of 3.06 and a debt-to-equity ratio of 0.43.

Lantheus (NASDAQ:LNTH) last issued its earnings results on Thursday, August 6th. The medical equipment provider reported $1.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.30 by $0.25. The firm had revenue of $388.18 million during the quarter, compared to analyst estimates of $363.23 million. Lantheus had a net margin of 17.69% and a return on equity of 28.10%. The business’s revenue was up 2.7% on a year-over-year basis. During the same period in the previous year, the firm earned $1.57 earnings per share. Analysts predict that Lantheus Holdings, Inc. will post 4.54 earnings per share for the current year.

Lantheus Profile

Lantheus Holdings, Inc (NASDAQ: LNTH) is a healthcare company that develops, manufactures and commercializes diagnostic and therapeutic products, with a focus on medical imaging and radiopharmaceuticals. Its products are used by physicians and healthcare providers to help detect, characterize and monitor disease.

The company’s portfolio includes PYLARIFY (piflufolastat F 18), a positron emission tomography imaging agent used to identify prostate-specific membrane antigen-positive lesions in men with prostate cancer, and DEFINITY, an ultrasound-enhancing agent used to improve cardiac ultrasound imaging.